Brain Natriuretic Peptide in Liver Cirrhosis and Fatty Liver
Correlation with Cardiac Performance
Keywords:
brain natriuretic peptide (BNP), post hepatitis C virus liver cirrhosis, fatty liver, echocardiographyAbstract
Objective: The aims of the present study were to assess the serum BNP level in patients with post hepatitis C liver cirrhosis and patients with fatty liver and to determine the correlation between BNP and the severity of liver disease and cardiac performance.
Methods: The study was conducted on 140 subjects subdivided into 3 groups: group 1 included 60 patients having post hepatitis C virus (HCV) liver cirrhosis; group 2 included 60 patients with nonalcoholic fatty liver disease (NAFLD); and group 3 included 20 healthy volunteers serving as a control group. All patients and volunteers were subjected to full physical examinations, laboratory evaluation of hemoglobin percent, liver and renal function tests, serum electrolytes, cholesterol, triglyceride, HBs antigen, HCV antibody and serum BNP levels, ECG, abdominal ultrasonography, and echocardiography.
Results: There was a significant increase in the BNP level in cirrhotic patients compared to the other two groups (p = 0.000), and it was correlated with the severity of liver disease assigned as Child's classification (p = 0.000). Also, there was a significant increase in the BNP level in cirrhotic patients with decompensation components compared to those without decompensation components (p = 0.000), history of hepatic encephalopathy (p = 0.000), history of variceal bleeding (p = 0.000), history of spontaneous bacterial peritonitis (p = 0.000), presence of ascites (p = 0.000) and portal vein diameter > 11 mm in abdominal ultrasound (p = 0.000), and prolonged QTc interval in ECG (p = 0.011). There was a significant increase in serum BNP in patients with cirrhosis with the following echocardiographic findings: IVST > 11 mm, PWT > 11 mm, LA diameter > 40 mm, EF% < 54%, and E/A ratio < 1 compared to those without these echocardiographic findings (p = 0.000).
Conclusion: BNP level increases in post hepatitis C cirrhotic patients and tends to decrease in fatty liver disease patients, and it is correlated with both the severity of liver disease and the morpho-functional cardiac changes. Given the ever-increasing prevalence of liver cirrhosis and fatty liver disease worldwide, it is important to understand the benefits and limitations of BNP as a heart failure biomarker in hepatic patients, where the relationship between BNP level and myocardial function is complex and is altered by the liver disease.
References
De Lemos JA, Mc Guire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet.
; 362: 316-22. doi: 10.1016/S0140-6736(03)13976-1.
Pimenta, J, Paulo C, Gomes A, Silva S, Rocha-Gonçalves F, Bettencourt P. B-type natriuretic peptide is
related to cardiac function and prognosis in hospitalized patients with decompnesated cirrhosis. Liver
International. 2010; 30: 1059–66. doi: 10.1111/j.1478-3231.2010.02266.x, PMID: 20492497.
Wong F, Siu S, Liu P, Blendis LM. Brain natriuretic peptide: is it a predictor of cardiomyopathy in
cirrhosis? Clin Sci. 2001; 101: 621-8. doi: 10.1042/cs1010621, PMID: 11724649.
Henriksen JH, Gotze JP, Fuglsang S, Christensen E, Bendtsen F, Møller S. Increased circulating pro-brain
natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to
cardiovascular dysfunction and severity of disease. Gut. 2003; 52: 1511-7. doi: 10.1136/gut.52.10.1511,
PMID: 12970147.
Padillo J, Rioja P, Muñoz-Villanueva MC, Vallejo JA, Ciria R, Muntane J, et al. BNP as marker of heart
dysfunction in patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2010; 22(11): 1331-6. doi:
1097/MEG.0b013e32833e6b2a, PMID: 20729741.
Radvan M, Svoboda P, Radvanová J, Stumar J, Scheer P. Brain natriuretic peptide in decompensation of
liver cirrhosis in non-cardiac patients. Hepatogastroenterology. 2009; 56(89): 181-5. PMID: 19453054.
Shi LY, Jin R, Lin CJ, Wu JS, Chen XW, Yu Z, Zhang PC. B-type natriuretic peptide and cirrhosis
Progression. Genet Mol Res. 2015; 14(2): 5188-96. doi: 10.4238/2015.May.18.9, PMID: 26125712.
Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease.
Atherosclerosis. 2007; 19(12): 235-40. doi: 10.1016/j.atherosclerosis.2006.08.021, PMID: 16970951.
Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver,
steatohepatitis, and the metabolic syndrome. Hepatology. 2003; 4: 917-23. doi: 10.1053/jhep.2003.50161,
PMID: 12668987.
Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, et al. Nonalcoholic fatty liver disease is
a novel predictor of cardiovascular disease. World J Gastroenterol. 2007; 13: 1579-84. doi:
3748/wjg.v13.i10.1579, PMID: 17461452, PMCID: PMC4146902.
Abid A, Taha O, Nseir W, Farah R, Grosovski M, Assy N. Soft drink consumption is associated with fatty
liver disease independent of metabolic syndrome. J Hepatol. 2009; 51: 918-24. doi:
1016/j.jhep.2009.05.033, PMID: 19765850.
Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver
disease. N Engl J Med. 2010; 363: 1341–50. doi: 10.1056/NEJMra0912063, PMID: 20879883.
Neeland IJ, Winders BR, Ayers CR, Das SR, Chang AY, Berry JD, et al. Higher Natriuretic Peptide Levels
Associate With a Favorable Adipose Tissue Distribution Profile. J Am Coll Cardiol. 2013; 62: 752–60. doi:
1016/j.jacc.2013.03.038, PMID: 23602771, PMCID: PMC3857334.
Sugisawa T, Kishimoto I, Kokubo Y, Nagumo A, Makino H, Miyamoto Y, et al. Visceral fat is negatively
associated with B-type natriuretic peptide levels in patients with advanced type 2 diabetes. Diabetes Res
Clin Pract. 2010; 89: 174–80. doi: 10.1016/j.diabres.2010.03.012, PMID: 20363521.
Cheng S, Fox CS, Larson MG, Massaro JM, McCabe EL, Khan AM, et al. Relation of visceral adiposity to
circulating natriuretic peptides in ambulatory individuals. Am J Cardiol. 2011; 108: 979–84. doi:
1016/j.amjcard.2011.05.033, PMID: 21813106, PMCID: PMC3175269.
Singh D, Das CJ, Baruah MP. Imaging of non alcoholic fatty liver disease: A road less travelled. Indian J
Endocrinol Metab. 2013; 17(6): 990-5. doi: 10.4103/2230-8210.122606, PMID: 24381873, PMCID:
PMC3872717.
Goldman MJ. Principles of clinical electrocardiography. 8th ed. Los Altos: Lange Medical cary. 1973; 24- 8.
Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, et al. Q-T Interval Prolongation
in Cirrhosis: Prevalence, Relationship With Severity, and Etiology of the Disease and Possible
Pathogenetic Factors. Hepatology. 1989; 27: 28-34. doi: 10.1002/hep.510270106, PMID: 9425913.
Gottdiener JS, Bendnarz I, Devereaux R, Gardin J, Klein A, Manning WJ, et al. American Society of
Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr.
; (17): 1086-119. doi: 10.1016/j.echo.2004.07.013, PMID: 15452478.
Devereaux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment
of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol. 1986; 57: 450-8. doi:
1016/0002-9149(86)90771-X, PMID: 2936235.
Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations:
echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol. 1976;
(1): 7-11. doi: 10.1016/0002-9149(76)90491-4, PMID: 1244736.
El Nakeeb NA, Esmat I, Bahaa M, Agwa SHA, Heidar MM. Evaluation of Cirrhotic Cardiomyopathy in
Patients with Liver cirrhosis by Brain Natriuretic Peptide and Echocardiography Pre and Post Liver
Transplantation. Life Science Journal. 2013; 10(2): 212-9.
Yilmaz VT, Eken C, Avci AB, Duman A, Tuna Y, Akin M. Relationship of increased serum brain
natriuretic peptide levels with hepatic failure, portal hypertension and treatment in patients with cirrhosis.
Turk J Gastroenterol. 2010; 21(4): 381-6. PMID: 21331991.
Krishnan A, Srinivasan V, Venkataraman J. Variceal recurrence, rebleeding rates and alterations in clinical
and laboratory parameters following post-variceal obliteration using endoscopic sclerotherapy. J Dig Dis.
; 596-600. doi: 10.1111/j.1751-2980.2012.00633.x, PMID: 23107447.
Redfield MR, Mahoney DW, Jacopsen SJ. Isolated diastolic dysfunction in the community. Circulation.
; Suppl: I-381
Maisel A. B-type natriuretic peptide in the diagnosis and management of congestive heart failure. Cardiol
Clin. 2001; 16: 557-71. doi: 10.1016/S0733-8651(05)70243-5.
Sharara AI, Rockey DC. Gastroesophageal variceal hemorrhage. N Engl J Med. 2001; 324: 669-81. doi:
1056/NEJMra003007, PMID: 11547722.
Licata A, Corrao S, Petta S, Genco C, Cardillo M, Calvaruso V, et al. NT Pro BNP Plasma Level and
Atrial Volume Are Linked to the Severity of Liver Cirrhosis. PLoS ONE. 2013; 8(8): e68364.
doi:10.1371/journal.pone.0068364.
Goland S, Shimoni S, Zornitzki T, Knobler H, Azoulai O, Lutaty G, et al. Cardiac abnormalities as a new
manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging
assessment. J Clin Gastroenterol. 2006; 40(10): 949-55. doi: 10.1097/01.mcg.0000225668.53673.e6,
PMID: 17063117.
Ramachandran S, Vasan MD, Martin G, Larson ScD, Emelia J, Benjamin MD, et al. Left Ventricular
Dilatation and the Risk of Congestive Heart Failure in People without Myocardial Infarction. N Engl J
Med. 1997; 336: 1350-5. doi: 10.1056/NEJM199705083361903, PMID: 9134875.
Fotbolcu H, Yakar T, Duman D, Karaahmet T, Tigen K, Cevik C, et al. Impairment of the left ventricular
systolic and diastolic function in patients with non-alcoholic fatty liver disease. Cardiol J. 2010; 17(5): 457- 63. PMID: 20865675.
Şerban A, Casoinic F, Bădău C. Diastolic dysfunction assessment by pulsed-wave and tissue Doppler
imaging in diabetic patients with nonalcoholic fatty liver disease. HVM Bioflux. 2012; 4(2): 58-62.
Bonapace S, Perseghin G, Molon G, Canali G, Bertolini L, Zoppini G, et al. Nonalcoholic Fatty Liver
Disease Is Associated With Left Ventricular Diastolic Dysfunction in Patients With Type 2 Diabetes.
Diabetes Care. 2012; 35: 389–95. doi: 10.2337/dc11-1820, PMID: 22210573 , PMCID: PMC3263884.
Aparci M, Isilak Z, Uz O, Kardesoglu E, Yiginer O, Sildiroglu O, et al. Increased P wave dispersion in
patients with liver steatosis. Med Glas (Zenica). 2010; 7(2): 143-7. PMID: 21258310.
Westerbacka J, Corner A, Tiikkainen M, Tamminen M, Vehkavaara S, Häkkinen AM, et al. Women and
men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women:
implications for sex differences in markers of cardiovascular risk. Diabetologia. 2004; 47: 1360–9. doi:
1007/s00125-004-1460-1, PMID: 15309287.
Pietilainen KH, Rissanen A, Kaprio J, Mäkimattila S, Häkkinen AM, Westerbacka J, et al. Acquired
obesity is associated with increased liver fat, intra-abdominal fat, and insulin resistance in young adult
monozygotic twins. Am J Physiol Endocrinol Metab. 2005; 288: 768–74. doi:
1152/ajpendo.00381.2004, PMID: 15585588.
Thamer C, Machann J, Haap M, Stefan N, Heller E, Schnödt B, et al. Intrahepatic lipids are predicted by
visceral adipose tissue mass in healthy subjects. Diabetes Care. 2004; 27: 2726–9. doi:
2337/diacare.27.11.2726, PMID: 15505012.
Horwich MD, Hamilton MD, Fonarow GC. B-Type Natriuretic Peptide Levels in Obese Patients With
Advanced Heart Failure. J Am Coll Cardiol. 2006; 47: 85–90.
Wang T, Larson M, Levy D, Benjamin E, Leip E, Wilson P, Ramachandran S. Impact of Obesity on
Plasma Natriuretic Peptide Levels. Circulation. 2004; 109: 594–600. doi:
1161/01.CIR.0000112582.16683.EA, PMID: 14769680.
Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM, et al. Impact of Body Mass and
Body Composition on Circulating Levels of Natriuretic Peptides: Results from the Dallas Heart Study.
Circulation. 2005; 112: 2163–8. doi: 10.1161/CIRCULATIONAHA.105.555573, PMID: 16203929.
Frankenstein L, Remppis A, Nelles M, Schaelling B, Schellberg D, Katus H, et al. Relation of N-terminal
pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity
status. Eur Heart J. 2008; 29: 2634–40. doi: 10.1093/eurheartj/ehn388, PMID: 18765456.
Krauser D, Chae C, Cameron R, Anwaruddin S, Baggish A, Chen A, et al. Effect of body mass index on
natriuretic peptide levels in patients with acute congestive heart failure: A ProBNP Investigation of
Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J. 2005; 149: 44–50. doi:
1016/j.ahj.2004.07.010, PMID: 15990762.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
